Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
December 24, 2008
KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) obtained approval for an additional regimen and dose (4,000 mg divided into two doses per day) of Pentasa® Tablets 250 and Pentasa® Tablets 500 (generic name: mesalazine) for the treatment of ulcerative colitis in its active phase. These products are intended for the treatment of ulcerative colitis and Crohn's disease.
Inflammatory bowel diseases (ulcerative colitis and Crohn's disease) are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine drugs like Pentasa and steroids.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.